Showing results (31-40 of 383) with videos related to
Sort By:
Pageof 39
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 29, 2021
Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5-Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open-Label Extension of a Randomized Controlled TrialAndrew Grey, Mark J Bolland, Anne Horne, et al.Bonekey Reports|August 17, 2013
Subgroup analysis for the risk of cardiovascular disease with calcium supplementsLoretta T Radford, Mark J Bolland, Greg D Gamble, et al.The Journal of Clinical Endocrinology and Metabolism|December 4, 2008
The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal womenAndrew Grey, Mark J Bolland, Diana Wattie, et al.The Journal of Clinical Endocrinology and Metabolism|January 13, 2005
Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiencyAndrew Grey, Jenny Lucas, Anne Horne, et al.Addiction (Abingdon, England)|October 20, 2010
Decreased bone density in men on methadone maintenance therapyAndrew Grey, Karla Rix-Trott, Anne Horne, et al.CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|September 13, 2017
Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trialAndrew Grey, Mark J Bolland, Anne Horne, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 14, 2013
Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trialAndrew Grey, Mark Bolland, Bobby Mihov, et al.BMJ Open|March 21, 2013
Differences between self-reported and verified adverse cardiovascular events in a randomised clinical trialMark J Bolland, Alan Barber, Robert N Doughty, et al.The Journal of Clinical Endocrinology and Metabolism|February 1, 2007
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trialAndrew Grey, Mark Bolland, Greg Gamble, et al.The Journal of Clinical Endocrinology and Metabolism|July 1, 2011
Stable bone density in HAART-treated individuals with HIV: a meta-analysisMark J Bolland, Tom K M Wang, Andrew Grey, et al.Pageof 39